Medtronic's ‘Artificial Pancreas’ gets FDA Approval for Diabetes

Medtronic's ‘Artificial Pancreas’ gets FDA Approval for Diabetes

The US Food and Drug Administration has approvedMiniMed 670G device of Medtronic Plcfor type 1 diabetes, the company announced in a statement. It is going to be the firstdeviceapproved as automated insulin delivery system.

The device, also known as anartificial pancreas, will helptype 1 diabetes patients by relieving them from frequent checks of insulin levels.It automatically regulates the insulin flowwith the help of a glucose sensor that is linked to an insulin pump.

People who are 14-year-old or above could use the device, stated Medtronic in its recent statement.

“The device offers type 1 diabeticsgreater freedom to live their lives without having to consistently and manually monitor baseline glucose levels and administer insulin”, saidDirector Jeffrey Shuren atmedical device division of the FDA.

It is an effective device to monitor glucose levels. MiniMed 670Gmeasures levels every five minutes and if it finds that there’s a need of insulin, itautomatically administers it. People who will be using the device have to inform it when they exercise because at that time their glucose levelswill be lowered.

Currently, people of type 1 diabetes takeinsulin injections various times every day. It is important for these people to keep on monitoring their blood sugar as it suddenly may drop to dangerous low levels. The new device will be a relief to these sufferers, said Derek Rapp of the Juvenile Diabetes Research Foundation.Rapp’s son is also a patient of type 1 diabetics and believes the new MiniMed 670G is going to be a life-saver for many with the disease.

Medtronic has not revealed the price of MiniMed 670G, but experts say it could cost around $5,000 to $8,000.


Share

Contact

Whether you want to ask us a question, would like to solve a problem, or just give us a suggestion, you’ll find many ways to contact us right here.

Email: editor@norcal.news

Phone: (916) 225-9835

Fax: (916) 225-9845

Newsletters

Subscribe and get the latest updates, news and more...